Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132483 | 1.00 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1WNT3AHRH3MEN1 | |
| SCHEMBL6132377 | 0.92 | WNT3A (0.40) | CSNK2A2CSNK2A1WNT3AHRH3MEN1 | |
| SCHEMBL6132376 | 0.91 | CSNK2A2 (0.46) | CSNK2A2CSNK2A1HRH3NR1H4USP2 | |
| Hydrochloric Acid SCHEMBL6132312 | 0.90 | CSNK2A2 (0.45) | CSNK2A2CSNK2A1HRH3NR1H4USP2 | |
| Hydrochloric Acid SCHEMBL6134979 | 0.90 | CSNK2A2 (0.45) | CSNK2A2CSNK2A1HRH3NR1H4USP2 | |
| SCHEMBL6132189 | 0.90 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1WNT3AHRH3MEN1 | |
| Hydrochloric Acid SCHEMBL6134551 | 0.89 | CSNK2A2 (0.43) | CSNK2A2CSNK2A1HRH3NR1H4USP2 | |
| SCHEMBL6133892 | 0.88 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1WNT3AHRH3MEN1 | |
| SCHEMBL6132429 | 0.85 | MEN1 (0.43) | MEN1KMT2AITGB3ITGA2BALOX15 | |
| SCHEMBL6132357 | 0.85 | MEN1 (0.43) | MEN1KMT2AITGB3ITGA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | CSNK2A2 1792/4885CSNK2A1 1184/4885WNT3A 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.